Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2024) 144 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2024-203004

Published: 2024

Journal Articles

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

Alfonso Piciocchi, Sabina Chiaretti, Marta Cipriani, Monica Messina, Loredana Elia, Irene Della Starza, Antonella Vitale, Paola Fazi, Marco Vignetti, Robin Foa

Blood (2023) 142 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2023-179102

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2023) 142 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2023-181813

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Deborah Cardinali, Irene Della Starza, Vittorio Bellomarino, Marco Beldinanzi, Mariangela Di Trani, Felicetto Ferrara, Monica Bocchia, Prassede Salutari, Monia Lunghi, Erika Borlenghi, Matteo Piccini, Catello Califano, Alfonso Piciocchi, Maria Stefania De Propris, Robin Foà, Sabina Chiaretti

Blood (2022) 140 (Supplement 1): 6350–6351.

https://doi.org/10.1182/blood-2022-163559

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis

Marco Beldinanzi, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Loredana Elia, Mabel Matarazzo, Mariangela Di Trani, Sabina Chiaretti, Robin Foà

Blood (2022) 140 (Supplement 1): 11866–11867.

https://doi.org/10.1182/blood-2022-163141

Published: 2022

Journal Articles

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Blood (2022) 140 (Supplement 1): 9226–9227.

https://doi.org/10.1182/blood-2022-162416

Published: 2022

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Irene Della Starza, PhD, Vittorio Nunes, Federica Lovisa, Daniela Silvestri, Marzia Cavalli, PhD, Andrea Garofalo, Mimma Campeggio, Lucia Anna De Novi, PhD, Carlotta Oggioni, Andrea Biondi, MD, Anna Guarini, PhD, Maria Grazia Valsecchi, PhD, Valentino Conter, MD, Giuseppe Basso, MD, Robin Foà, MD, Giovanni Cazzaniga, PhD

Blood (2018) 132 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2018-99-117954

Published: 2018

Journal Articles

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

Blood (2018) 132 (Supplement 1): 658.

https://doi.org/10.1182/blood-2018-99-114177

Published: 2018

Journal Articles

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Alessandro Pulsoni, MD, Irene Della Starza, PhD, Maria Elena Tosti, statistician, Luca Vincenzo Cappelli, Giorgia Annechini, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Gianna Maria D'Elia, Lavinia Grapulin, MD, Anna Guarini, Ilaria Del Giudice, MD PhD, Robin Foa

Blood (2016) 128 (22): 2959.

https://doi.org/10.1182/blood.V128.22.2959.2959

Published: 2016

NARROW

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter,Report from the Campus ALL/Gimema Network

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only